{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43.3","upperLimit":"71.4","value":"55.6"},{"groupId":"OG001","lowerLimit":"40.6","upperLimit":"72.5","value":"54.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"description":"Kaplan-Meier estimate of the probability of being alive and free of relapse or second malignancy three years after protocol enrollment","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received Cytarabine + Daunorubicin + Etoposide as their first course of chemotherapy. Subsequent therapy is risk-adapted.","id":"OG000","title":"Cytarabine+Daunorubicin+Etoposide"},{"description":"Patients received Clofarabine + Cytarabine as their first course of chemotherapy. Subsequent therapy is risk- adapted.","id":"OG001","title":"Clofarabine+Cytarabine"}],"paramType":"NUMBER","populationDescription":"Randomized standard risk patients who received chemotherapy only","reportingStatus":"POSTED","timeFrame":"3 years after completion of therapy","title":"Event-free Survival of Standard Risk Patients Who Receive Chemotherapy Alone.","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}